January 30, 2014
Applied Tissue Technologies LLC announces news in advanced wound care with:
The issuance of a new patent simplifying the use of negative pressure wound therapy with a breakthrough design. The USPTO patent entitled “Wound Treatment Device Employing Negative Pressure,” was issued on January 21, 2014.
The technology simplifies the administration of negative pressure wound therapy “NPWT” treatment by eliminating the traditional methods for dispersing negative pressure throughout the wound. The design is configured for the device to come into direct contact with the wound by utilizing a single layer of material that embodies air channels for even distribution of negative pressure and also serves as the wound dressing. Additionally the inner facing surface of the device which contacts the wound contains structures that exert micromechanical forces throughout the wound-bed to stimulate the formation of granulation tissue. It should be noted that this device is NOT an irrigation system, rather it is a delivery platform enabling precision and comprehensive treatment of wounds by creating a micro-environment.
The technology supporting USPTO patent number 8,632,523 is a component of Applied Tissue’s platform technology. The technology is designed to be a comprehensive wound treatment platform covering treatment from the point of injury to delivery of pain and infection control modalities and administration of treatment to minimize scar.
“We are very pleased with the issue of this patent. Testing and validation have been ongoing with excellent results. We aim to bring this advance in wound healing technology to patients in short order,” said Michael Broomhead, CEO of Applied Tissue Technologies LLC.
The issuance of this patent adds to a growing intellectual property portfolio for Applied Tissue and is further supported by a number of pending applications globally.
The NPWT platform technology is an intuitive addition to Applied Tissue’s current product offering and technology development of advanced wound care devices. The platform will be supported by the Xpansion® Micro-Autografting kit, Wound Chamber device, and gene microseeding device. The Xpansion® Micro-Autografting kit is exclusively distributed in the Western Hemisphere by SteadMed.
Applied Tissue Technologies was founded in 2000 with the mission to bring medical innovation driven by science to patients.
For further information about Applied Tissue Technologies or its products please contact:
Applied Tissue Technologies
275 Grove Street
Newton, MA 02466